✦ LIBER ✦

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology

✍ Scribed by David Scott Miller; John A. Blessing; Richard D. Drake; Robert Higgins; D. Scott McMeekin; Louis V. Puneky; Carolyn N. Krasner

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of pemetrexed (Alimta, LY2315

✍ David Scott Miller; John A. Blessing; Diane C. Bodurka; Albert J. Bonebrake; Joh 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 155 KB

A phase II study of gemcitabine (gemzar,

✍ David L. Tait; John A. Blessing; James S. Hoffman; Kathleen N. Moore; Nick M. Sp 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Dactinomycin in the Treatment of Recurre

✍ David H. Moore; John A. Blessing; Charles Dunton; Richard E. Buller; Gary C. Rei 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 33 KB

A phase II evaluation of aflibercept in

✍ Robert L. Coleman; Michael W. Sill; Heather A. Lankes; Amanda Nickles Fader; Nei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 246 KB

A phase II evaluation of weekly docetaxe

✍ Agustin A. Garcia; John A. Blessing; Susan Nolte; Robert S. Mannel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Evaluation of irofulven (MGI-114) in the

✍ Russell J. Schilder; John A. Blessing; Michael L. Pearl; Peter G. Rose 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 67 KB